|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013227,
umls-concept:C0023452,
umls-concept:C0031809,
umls-concept:C0086047,
umls-concept:C0282443,
umls-concept:C0376298,
umls-concept:C0392920,
umls-concept:C0599894,
umls-concept:C0600688,
umls-concept:C1512888,
umls-concept:C1521840,
umls-concept:C1552617
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2010-4-20
|
|
pubmed:abstractText |
One of the challenges of incorporating molecularly targeted drugs into multi-agent chemotherapy (backbone) regimens is defining dose-limiting toxicities (DLTs) of the targeted agent against the background of toxicities of the backbone regimen. An international panel of 22 pediatric acute lymphocytic leukemia (ALL) experts addressed this issue (www.ALLNA.org). Two major questions surrounding DLT assessment were explored: (1) how toxicities can be best defined, assessed, and attributed; and (2) how effective dosing of new agents incorporated into multi-agent ALL clinical trials can be safely established in the face of disease- and therapy-related systemic toxicities. The consensus DLT definition incorporates tolerance of resolving Grade 3 and some resolving Grade 4 toxicities with stringent safety monitoring. This functional DLT definition is being tested in two Children's Oncology Group (COG) ALL clinical trials.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20127846-14726387,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20127846-16351633,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20127846-16407512,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20127846-16857985,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20127846-17584026,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20127846-17584030,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20127846-18086342,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20127846-18182661,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20127846-18324639,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20127846-18345718,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20127846-18711187,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20127846-9787315
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1545-5017
|
|
pubmed:author |
pubmed-author:ALLNA 2008 Conference,
pubmed-author:ArceciRobert JRJ,
pubmed-author:BiondiAndreaA,
pubmed-author:BorowitzMichael JMJ,
pubmed-author:BrownPatrickP,
pubmed-author:CarrollWilliam LWL,
pubmed-author:GaynonPaul SPS,
pubmed-author:GoreLiaL,
pubmed-author:HortonTerzah MTM,
pubmed-author:HungerStephen PSP,
pubmed-author:JehaSimaS,
pubmed-author:KearnsPamela RPR,
pubmed-author:MaurerBarry JBJ,
pubmed-author:NarendranAruA,
pubmed-author:RaetzElizabeth AEA,
pubmed-author:ReynoldsC PatrickCP,
pubmed-author:SiegelStuart ESE,
pubmed-author:SilvermanLewis BLB,
pubmed-author:SmithMalcolm AMA,
pubmed-author:SpostoRichardR,
pubmed-author:WhitlockJames AJA,
pubmed-author:WinickNaomi JNJ,
pubmed-author:ZwaanC MichelCM
|
|
pubmed:copyrightInfo |
Copyright 2010 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
54
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
872-8
|
|
pubmed:dateRevised |
2011-9-26
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.
|
|
pubmed:affiliation |
Texas Children's Cancer Center/Baylor College of Medicine, Houston, Texas 77030, USA. tmhorton@txccc.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Consensus Development Conference,
Research Support, N.I.H., Extramural
|
